Skip to content

CareDx CDNA Restricted Cash

Restricted Cash at other companies

GeneDx Holdings logo
GeneDx HoldingsWGS
$992K+0.2%
TransMedics Group, Inc. logo
TransMedics Group, Inc.TMDX
$18.44M+3,588%
Veracyte logo
VeracyteVCYT
$1.66M+0.7%
Guardant Health logo
Guardant HealthGH
$112.15M+6.5%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's restricted cash?
CareDx (CDNA) reported restricted cash of $551K in Q1 2026.
How has CareDx's restricted cash changed year-over-year?
CareDx's restricted cash increased by 0.2% year-over-year, from $550K to $551K.
What is the long-term trend for CareDx's restricted cash?
Over 5 years (2020 to 2025), CareDx's restricted cash has grown at a 15.3% compound annual growth rate (CAGR), from $270K to $551K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.